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Available online 3 July 2010In this issue of the journal Hoogwegt et al. describes the
results of smoking cessation on quality of life (QoL) after
vascular surgery. This is an ambition they should be
applauded for; smoking cessation is most often recom-
mended but seldom evaluated. In their cohort of patients
they report QoL five years after surgery related to patients
smoking status at three years after surgery. In summary
they found that smoking cessation did not impair QoL
among patients undergoing vascular surgery, (in contrast to
what many smokers state as an argument to continue
smoking). They also found that current smokers have worse
QoL than the combined group of ex-smokers and never
smokers. This is important since they all have advanced
vascular disease, but despite this it is possible to improve
QoL among smokers.
The authors did not find any QoL-improvement in those
defined as quitters (those who stopped smoking between
baseline and three years after surgery) when compared to
current smokers. So is this a finding to be disappointed
about? I would say maybe not, the presented data gives
a more optimistic picture. Although there was no statisti-
cally significant improvement, all Odds ratios from multi-
variate analysis were less than 1.0 e indicating that there
might be insufficient power to prove such an effect. The* Tel.: þ46 736200636; fax: þ46 86162309.
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doi:10.1016/j.ejvs.2010.06.004number of quitters (nZ 55, 14%) tell us two things, a type II
error can not be excluded and also e the smoking cessation
therapy can be improved. There is no similar study after
vascular surgery but previous results from Mulder et al.
showed that ex-smokers had better QoL irrespective of
time since they quit.1
To Study the Effects of Smoking and Smoking
Cessation
When studying tobacco exposure the exposure needs to be
properly categorised. At least data have to allow catego-
risation as active smoker, former smoker and never
smoked. When the term former smoker is used it should be
used with a definition. There is no universal definition on
what a former smoker is but looking at perioperative risks,
an interval of 4e8 weeks of abstinence is probably suffi-
cient.2 Using longer periods of abstinence (3e6 months) for
a definition of a former smoker will increase likelihood of
underestimating the risks with smoking since some of those
categorised as smokers will in fact be non-smokers at the
time of surgery. For longer follow-up periods, repeat
smoking status should be assessed since smoking unfortu-
nately sometimes is a dynamic variable. Smoking cessation
is also recommended to be reported as prolonged absti-
nence which helps sorting out some definition problems.3
Prolonged (or continuous) abstinence simply means thatd by Elsevier Ltd. All rights reserved.
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point of follow-up. Also, as Hoogwegt et al. point out, the
dose of smoking may sometimes be important. When look-
ing at the development of vascular disease over time, such
as asymptomatic carotid stenosis or abdominal aortic
aneurysms, it would help to collect the dose of exposure to
estimate the contribution of smoking. Pack-years is the
simplest and most common tool for estimating dose. One
pack-year is defined as 20 cigarettes smoked per day for
one year ((number of cigarettes smoked per day  number
of years smoked)/20).
Do We Need More Information or More Action?
Although smoking is a known predictor of poor prognosis
for most vascular diseases the effect of smoking cessation
is poorly studied. As the authors correctly point out, the
knowledge of QoL in relation to smoking cessation is even
poorer. When designing trials of medically controlled arms
for intermittent claudication for example, smoking cessa-
tion should be an integral part of the intervention and the
protocols must be designed to evaluate the effect of
abstinence from smoking. Also the effect of smoking
cessation on progression of asymptomatic carotid stenosis
and small abdominal aortic aneurysms remains to be
elucidated. Without evidence it is difficult to inform
patients and to adequately allocate resources. Maybevascular surgeons and interventionalists cannot only
sharpen their knives and improve stents. They also have to
improve the evidence-based care of smoking addiction.
Written protocols and nurses and physicians professionally
trained will increase smoking cessation standards
substantially. Smoking cessation is evidence-based medi-
cine and not a lottery.4,5 Although we all remember those
patients that fail to succeed in smoking cessation, this
must not lead to poor treatment of all those who can
succeed.
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